A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

ConditionBurns
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Manitoba

About this trial

Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajet™) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.

Eligibility criteria

Qualifiers

Persons with bilateral limb partial thickness burn injuries of similar depth requiring admission

Disqualifiers

Total body surface area (TBSA) of burn >30%.

Burn depth full thickness or deeper on initial assessment.

Prior excision at another healthcare centre.

Patients with pre-existing malnutrition

Trial design

Treatments tested in this trial

  • Standard dressing
  • PluroGel

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators